ANTI-HEPATITIS B VIRUS DRUG
|Posted date||Mar 29, 2017|
|International application number||2016JP069793|
|International publication number||WO 2017010330|
|Date of international filing||Jul 4, 2016|
|Date of international publication||Jan 19, 2017|
|Title||ANTI-HEPATITIS B VIRUS DRUG|
|Abstract||Provided is a novel anti-hepatitis B virus (HBV) drug that has a different function mechanism (a target molecule) from existing medicines. The anti-HBV drug comprises a compound represented by formula (I), a tautomer thereof or a salt or solvate of the same [in formula (I), R1, R2 and R3 are the same or different and represent an optionally substituted C1-6 alkyl group or an optionally substituted aromatic group].|
|Outline of related art and contending technology||
A hepatitis virus (HBV) chronic hepatitis B cirrhosis or the liver is one of the 1 leading cause of cancer. Current, (about 110 million) Japanese 0.9% is estimated to be HBV and carrier, about 3 million of the world and is considered to be the presence of a carrier. Prevention of infection is HBV vaccine have been developed, some anti-HBV drugs may also has been already present, lamivudine, adefovir, entecavir are on the market are the. And these are all nucleic acid analogs, having a function of the reverse transcription polymerase HBV DNA targets. By the use of these, HBV in blood is lost. However, the various forms of the stable within the cells in the liver HBV DNA exists as, discontinuation of the chemotherapy by an anti-viral agent, there is the risk of relapse of hepatitis. In addition, drug resistance to existing anti-HBV agent virus is also reported. For this reason, the existing mechanism of action of a drug different (target molecule), the development of new anti-HBV agents has been desired.
On the other hand, as the triazine derivatives -6 - pyrimido 1, 2-a1, 3, 5, many compounds have been reported (non-patent document 1 and non-patent document 2). However, triazine derivatives and anti-pyrimido 1, 2-a1, 3, 5 active HBV -6 - in terms of the relationship has never been hitherto been reported.
|IPC(International Patent Classification)|
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ Please contact us by E-mail if you have any interests on this patent.
Contact Information for " ANTI-HEPATITIS B VIRUS DRUG "
- KAGOSHIMA UNIVERSITY The Intellectual Property & Risk Management Department
- URL: https://www.krcc.kagoshima-u.ac.jp/contact/contact/
- Address: Korimoto 1-21-24, Kagoshima, Japan , 890-8580
- Fax: 81-99-285-3886